|
| Press Releases |
|
 |
|
| Wednesday, December 11, 2024 |
|
|
Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership |
| As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by robust R&D capabilities and exceptional commercialization expertise. more info >> |
|
| Wednesday, December 4, 2024 |
|
|
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy |
| Everest Medicines (HKEX 1952.HK,"Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor. more info >> |
|
| Monday, December 2, 2024 |
|
|
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong |
| Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everests New Drug Application (NDA) for VELSIPITY (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis. more info >> |
|
| Friday, November 29, 2024 |
|
|
NEFECON(R) Included in National Reimbursement Drug List (NRDL) |
| On November 28, the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security announced the 'National Reimbursement Drug List (2024)' (NRDL), which will officially take effect on January 1, 2025. NEFECON(R), the first etiological treatment for IgA nephropathy developed by Everest Medicines, was successfully included in the NRDL. more info >> |
|
| Tuesday, November 19, 2024 |
|
|
Everest Medicines Announces NEFECON(R)'s Full Approval in South Korea |
| Today, Everest Medicines announced that NEFECON(R) has received full approval from the Ministry of Food and Drug Safety (MFDS) in South Korea, indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion =1.0 g/day (or urine protein-to-creatinine ratio =0.8 g/g). This approval further expands NEFECON(R)'s footprint in Asia and provides Asian patients with a groundbreaking etiological treatment option for IgAN. more info >> |
|
| Friday, October 25, 2024 |
|
|
Everest Medicines Announces the Launch of VELSIPITY(R) in the Guangdong-Hong Kong-Macau Greater Bay Area |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that, through the "Hong Kong and Macau Medicine and Equipment Connect" policy, VELSIPITY(R) has officially been approved for patients with moderately to severely active ulcerative colitis (UC) by the Guangdong Provincial Medical Products Administration and can first be used in the Foshan Fosun Chancheng Hospital and the First Affiliated Hospital of Sun Yat-sen University, two of the medical institutions designated by the "Hong Kong and Macau Medicine and Equipment Connect" policy in the Greater Bay Area. more info >> |
|
| Tuesday, October 22, 2024 |
|
|
Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON Global Phase 3 NefIgArd Clinical Trial |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the "Kidney 360" magazine has published the complete two-year subpopulation data from Chinese patients in the Phase 3 NefIgArd clinical trial of NEFECON under the title "Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NefIgArd Trial Results". more info >> |
|
| Monday, October 21, 2024 |
|
|
Everest Medicines Announces Taiwan TFDA Approval of NEFECON for the Treatment of Primary IgA Nephropathy |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Administration (TFDA) has approved NEFECON indicated "to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression1". There are no restrictions on initial proteinuria levels in the approved indication. more info >> |
|
| Friday, October 18, 2024 |
|
|
Everest Medicines' Stock Price Rises by 20% as Profit Potential Drives Valuation Recovery |
| Everest Medicines (1952.HK) closed today with a 20.46% increase, hitting a high of HKD 28.6. The company's stock price has been steadily rising since the release of its interim results, with today's trading volume reaching HKD 291 million. Market updates show that BOCOM International released a report assigning an 'outperform' rating to the Chinese pharmaceutical sector, with Everest Medicines being one of the key recommended stocks. more info >> |
|
| Wednesday, October 2, 2024 |
|
|
NEFECON Included in 2024 KDIGO Clinical Practice Guidelines |
| Recently, Everest Medicines has announced another positive development. The company's lead product, NEFECON, as the only in-disease IgA nephropathy (IgAN) treatment, has been included in the "KDIGO 2024 Clinical Practice Guideline for the Management Of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)" (hereinafter referred to as the "New Guidelines (Draft)"), recommending treatment with a 9-month course of NEFECON for patients who are at risk of progressive kidney function loss with IgAN (2B). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
GFEAI 2025 Concludes Successfully: PM Paetongtarn Backs Human-Centric AI, AIGPC Emerges as Regional AI Ethics Hub
Jul 2, 2025 22:20 HKT/SGT
|
|
|
TravelKon Launches Unlimited Europe eSIM Range to Keep Australians Connected over European Summer Getaway
Jul 2, 2025 22:03 HKT/SGT
|
|
|
Global Sports Brand U.S. Polo Assn. Launches in Brazil With Grupo Pasquini
Jul 2, 2025 19:00 HKT/SGT
|
|
|
Baguio Awarded Marine Department Contract for Marine Cleansing in the Eastern Waters of Hong Kong for Approximately HK$150 million
Jul 2, 2025 17:51 HKT/SGT
|
|
|
Ching Lee Holdings (3728. HK) Reports Solid and Resilient Annual Results 
Jul 2, 2025 16:58 HKT/SGT
|
|
|
Mitsubishi Motors Launches the All-New Grandis for the European Market
Jul 2, 2025 12:10 JST
|
|
|
Valuufy partners with Mainichi Future Creation Lab, Supporting New Approaches to Business Sustainability
Jul 2, 2025 12:00 JST
|
|
|
Fujitsu launches solution to enhance customers' global supply chain resilience
Jul 2, 2025 11:32 JST
|
|
|
MHI Receives Order to Supply Four Circulating Water Pumps for Units 5 and 6 of Sanmen Nuclear Power Plant in China Under Collaboration with Dongfang Electric Machinery
Jul 2, 2025 11:30 JST
|
|
|
The Future Is Now! The Philippines Leads the AI-Powered Cloud Revolution
Jul 2, 2025 08:59 HKT/SGT
|
|
|
Multi-purpose Arena in Odaiba Aomi Area TOYOTA ARENA TOKYO Construction Completed
Jul 1, 2025 22:56 JST
|
|
|
1Finity, a Fujitsu company, commences operations and reveals brand identity
Jul 1, 2025 22:53 JST
|
|
|
MHI Thermal Systems Begins Field Test of Jointly Developed "Surplus Renewable Energy Absorption and Release System"
Jul 1, 2025 22:40 JST
|
|
|
Japan's Telecommunications Carriers Strengthen Disaster Response Through Collaborative Information Sharing
Jul 1, 2025 22:30 JST
|
|
|
DASA, Latin America's Largest Diagnostic Provider, Selects AGFA HealthCare's Enterprise Imaging Platform in Flagship Agreement
Jul 1, 2025 16:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
